Cftr Trikafta denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues a "Not FDA-Approved" Denial for Trikafta

This denial reason is most commonly issued in one of two situations: (1) the plan's system incorrectly flagged the drug, or (2) the specific use being requested (patient age, weight category, or mutation type) does not yet appear in the plan's internal clinical criteria as an approved indication — even if FDA approval has been granted or expanded. Trikafta has undergone multiple FDA label expansions since its original approval. If the denial cites lack of FDA approval, the first step is to verify whether the denial reflects an administrative error or a genuinely off-label use, then respond accordingly.

## Your Federal Appeal Rights

Under ACA §2719, non-grandfathered plans must provide internal and external appeals. Under ERISA §503, employer plans must provide full-and-fair review of all adverse benefit determinations, including those citing lack of regulatory approval. You have 180 days from the denial notice to file an internal appeal, and typically four months after an internal denial to request independent external review. Expedited review is available in urgent circumstances.

## The Concrete Appeal Process

1. Obtain the exact denial language — ask BCBS to specify which indication or patient characteristic it contends is not FDA-approved. 2. Pull the current FDA prescribing label (available on FDA.gov and the manufacturer's website) and confirm the approved indications. If the denial reflects a now-superseded label, document the current approval date and scope. 3. File a written internal appeal attaching the current FDA label and a prescriber letter confirming the prescribed use falls within the approved indication. 4. If denied internally, escalate to independent external review — IRO reviewers are required to apply current clinical standards, not outdated plan criteria.

## Documentation to Gather

• Current FDA prescribing label downloaded from FDA.gov, with the relevant indication highlighted
• Confirmed CFTR genotype report showing the mutation(s) covered under the applicable FDA-approved indication
• Prescriber attestation letter explicitly confirming the prescribed use is within FDA approval for this patient's documented genotype and age
• Clinical notes confirming patient demographics and clinical status
• Any FDA approval expansion announcements relevant to this patient's age group or mutation profile, if the plan's criteria lag a recent label update

## Criteria-Mapping Structure

Request the plan's current clinical coverage policy and compare it against the current FDA label:

| Plan Denial Basis | Rebuttal Evidence | |---|---| | Specific indication not FDA-approved | Current FDA label excerpt + approval date | | Patient characteristic outside approved use | Genotype report + label indication language | | Plan criteria predates label expansion | FDA approval letter or Federal Register notice |

If the prescribed use is unambiguously within the current FDA-approved labeling, a not-FDA-approved denial is among the most straightforwardly reversible — IRO reviewers consistently overturn denials where the plan's internal criteria have not been updated to reflect current labeling.